Literature DB >> 20943404

1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-Δ(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor.

John W Huffman1, Seon A Hepburn, Nataliya Lyutenko, Alicia L S Thompson, Jenny L Wiley, Dana E Selley, Billy R Martin.   

Abstract

Δ(8)-Tetrahydrocannabinol (26), 3-(1',1'-dimethylbutyl)- (12), 3-(1',1'-dimethylpentyl)- (13), 3-(1',1'-dimethylhexyl)- (14) and 3-(1',1'-dimethylheptyl)-Δ(8)-tetrahydrocannabinol (15) have been converted into the corresponding 1-bromo-1-deoxy-Δ(8)-tetrahydrocannabinols (25, 8-11). This was accomplished using a protocol developed in our laboratory in which the trifluoromethanesulfonate of a phenol undergoes palladium mediated coupling with pinacolborane. Reaction of this dioxaborolane with aqueous-methanolic copper(II) bromide provides the aryl bromide. The affinities of these bromo cannabinoids for the cannabinoid CB(1) and CB(2) receptors were determined. All of these compounds showed selectivity for the CB(2) receptor and one of them, 1-bromo-1-deoxy-3-(1',1'-dimethylhexyl)-Δ(8)-tetrahydrocannabinol (10), exhibits 52-fold selectivity for this receptor with good (28nM) affinity.
Copyright © 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20943404      PMCID: PMC2978510          DOI: 10.1016/j.bmc.2010.09.061

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  33 in total

1.  CB2 cannabinoid receptor-mediated peripheral antinociception.

Authors:  T P Malan; M M Ibrahim; H Deng; Q Liu; H P Mata; T Vanderah; F Porreca; A Makriyannis
Journal:  Pain       Date:  2001-09       Impact factor: 6.961

2.  3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor.

Authors:  J W Huffman; J Liddle; S Yu; M M Aung; M E Abood; J L Wiley; B R Martin
Journal:  Bioorg Med Chem       Date:  1999-12       Impact factor: 3.641

3.  Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor.

Authors:  N E Buckley; K L McCoy; E Mezey; T Bonner; A Zimmer; C C Felder; M Glass; A Zimmer
Journal:  Eur J Pharmacol       Date:  2000-05-19       Impact factor: 4.432

4.  HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor.

Authors:  L Hanus; A Breuer; S Tchilibon; S Shiloah; D Goldenberg; M Horowitz; R G Pertwee; R A Ross; R Mechoulam; E Fride
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

5.  Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat.

Authors:  Silvia Conti; Barbara Costa; Mariapia Colleoni; Daniela Parolaro; Gabriella Giagnoni
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 6.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

7.  Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists.

Authors:  John W Huffman; Gulay Zengin; Ming-Jung Wu; Jianzhong Lu; George Hynd; Kristen Bushell; Alicia L S Thompson; Simon Bushell; Cindy Tartal; Dow P Hurst; Patricia H Reggio; Dana E Selley; Michael P Cassidy; Jenny L Wiley; Billy R Martin
Journal:  Bioorg Med Chem       Date:  2005-01-03       Impact factor: 3.641

8.  CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain.

Authors:  N Clayton; F H Marshall; C Bountra; C T O'Shaughnessy
Journal:  Pain       Date:  2002-04       Impact factor: 6.961

9.  Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.

Authors:  Gerard M P Giblin; Celestine T O'Shaughnessy; Alan Naylor; William L Mitchell; Andrew J Eatherton; Brian P Slingsby; D Anthony Rawlings; Paul Goldsmith; Andrew J Brown; Carl P Haslam; Nick M Clayton; Alex W Wilson; Iain P Chessell; Andrew R Wittington; Richard Green
Journal:  J Med Chem       Date:  2007-05-04       Impact factor: 7.446

Review 10.  Marijuana, immunity and infection.

Authors:  T W Klein; H Friedman; S Specter
Journal:  J Neuroimmunol       Date:  1998-03-15       Impact factor: 3.478

View more
  5 in total

Review 1.  Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential.

Authors:  Peng Yang; Lirong Wang; Xiang-Qun Xie
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 2.  Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation.

Authors:  Slava Rom; Yuri Persidsky
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-08       Impact factor: 4.147

3.  Paternal activation of CB2 cannabinoid receptor impairs placental and embryonic growth via an epigenetic mechanism.

Authors:  Elisa Innocenzi; Emanuela De Domenico; Fabio Ciccarone; Michele Zampieri; Gabriele Rossi; Rosella Cicconi; Roberta Bernardini; Maurizio Mattei; Paola Grimaldi
Journal:  Sci Rep       Date:  2019-11-19       Impact factor: 4.379

4.  Synthesis of Functionalized Cannabilactones.

Authors:  Yingpeng Liu; Thanh C Ho; Mohammed Baradwan; Maria Pascual Lopez-Alberca; Christos Iliopoulos-Tsoutsouvas; Spyros P Nikas; Alexandros Makriyannis
Journal:  Molecules       Date:  2020-02-06       Impact factor: 4.411

Review 5.  CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections.

Authors:  M F Nagoor Meeran; Charu Sharma; Sameer N Goyal; Sanjay Kumar; Shreesh Ojha
Journal:  Drug Dev Res       Date:  2020-11-15       Impact factor: 5.004

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.